| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | RITA | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | 0.0048 | 1 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.0018 | 1 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | -0.0028 | 1 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | -0.0043 | 1 |
| mRNA | vorapaxar | CTRPv2 | pan-cancer | AAC | 0.002 | 1 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0018 | 1 |